arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Elicio Therapeutics, Inc.

ELTX
$1.40 ▼ -0.16 (-10.26%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
27 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
23
Health
Poor
Bearish
auto_awesome

Analytical Summary

Elicio Therapeutics, Inc. faces fundamental challenges with weakness in Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $26.9M
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -47.2% ↗
FCF / Share $-0.42 ↗
Trailing P/E —
Price / Book 3.9x
FCF Yield —
Debt / Equity 1.20
info Valuation on last close. End-of-day price, Nov 5, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
— —
Net Income Profit after all expenses
$-11.82M
↓ -5.5% —
FCF / Share Free cash flow per share
$-0.42
↑ +33.6% —
Long-Term Debt Long-term obligations
$9.54M
↑ +0.6% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Financial Health
4
Cash Quality →
62

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 7 years · 27 quarters